X0306 4 2017-08-23 1 0001169987 HTG MOLECULAR DIAGNOSTICS, INC HTGM 0001388325 Novo Holdings A/S TUBORG HAVNEVEJ 19 HELLERUP G7 2900 DENMARK 0 0 1 0 COMMON STOCK 2017-08-23 4 S 0 47162 2.0244 D 1102651 D COMMON STOCK 2017-08-24 4 S 0 382437 1.9086 D 720214 D COMMON STOCK 2017-08-25 4 S 0 720214 1.7503 D 0 D SERIES E PREFERRED STOCK WARRANTS (RIGHT TO BUY) 14.00 2022-01-14 COMMON STOCK 49786 49786 D The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $1.95 to $2.07, inclusive. Novo Holdings A/S ("Novo") undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote. This total does not include 49,786 shares of common stock subject to warrants which were erroneously reported as having been exercised in connection with the Issuer's IPO on a Form 4 filed May 12, 2015. Thus, the holdings of common stock reported by Novo since the May 12, 2015 filing have overstated the total shares held by 49,786 shares. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $1.900 to $2.045, inclusive. Novo undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $1.75 to $1.87, inclusive. Novo undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote. These warrants have no expiration date and are convertible at any time at the holder's election. These warrants were erroneously reported as exercised at the time of the IPO on the Form 4 filed May 12, 2015. The warrants are unexercised and, as of the date of this filing, Novo does not hold any shares of common stock but continues to hold the warrants. Novo Holdings A/S ("Novo") is a Danish limited liability company. The board of directors of Novo (the "Novo Board"), which is currently comprised of Sten Scheibye, Goran Ando, Jeppe Christiansen, Steen Riisgaard, Lars Rebien Sorensen and Per Wold-Olsen, has shared investment and voting control over the securities of the Issuer held by Novo (the "Shares") and may exercise such control only with the support of a majority of the Novo Board. As such, no individual member of the Novo Board is deemed to hold any beneficial ownership or reportable pecuniary interest in the Shares. /s/ Peter Haahr, Chief Financial Officer of Novo Holdings A/S 2017-08-25